The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,304.00
Bid: 12,304.00
Ask: 12,306.00
Change: -100.00 (-0.81%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

21 May 2014 11:28

RNS Number : 6882H
Bank of America Merrill Lynch
21 May 2014
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Pfizer Inc

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - US7170811035

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

5,573,264

0.087%

7,501,833

0.118 %

(2)

Derivatives (other thanoptions):

100,000

0.0%

0.821%

(3)

Options and agreements topurchase/sell:

11,551,000

0.181%

17,529,400

0.275 %

TOTAL:

17,224,264

0.27%

25,031,233

0.39%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Purchase

14,902

29.25 USD

Common - ISIN US7170811035

Purchase

3,941

29.28 USD

Common - ISIN US7170811035

Purchase

100

29.365 USD

Common - ISIN US7170811035

Purchase

2,200

29.37 USD

Common - ISIN US7170811035

Purchase

6,000

29.38 USD

Common - ISIN US7170811035

Purchase

100

29.395 USD

Common - ISIN US7170811035

Purchase

703

29.4 USD

Common - ISIN US7170811035

Purchase

2,200

29.41 USD

Common - ISIN US7170811035

Purchase

181

29.481 USD

Common - ISIN US7170811035

Purchase

2,976

29.49 USD

33303

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Sale

28,310

29.25 USD

Common - ISIN US7170811035

Sale

3,941

29.28 USD

Common - ISIN US7170811035

Sale

5,000

29.315 USD

Common - ISIN US7170811035

Sale

12,790

29.32 USD

Common - ISIN US7170811035

Sale

1,000

29.323 USD

Common - ISIN US7170811035

Sale

8,134

29.325 USD

Common - ISIN US7170811035

Sale

15,300

29.33 USD

Common - ISIN US7170811035

Sale

1,000

29.333 USD

Common - ISIN US7170811035

Sale

4,200

29.335 USD

Common - ISIN US7170811035

Sale

13,200

29.34 USD

Common - ISIN US7170811035

Sale

200

29.345 USD

93075

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN US7170811035

Swaps

Short

181

29.484 USD

Common - ISIN US7170811035

Swaps

Long

824

29.319 USD

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - GB0009895292/ ADR - US0463531089

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

9,116

0.001%

11,677

0.001 %

(2)

Derivatives (other thanoptions):

0

0%

0

0%

(3)

Options and agreements topurchase/sell:

135,200

0.011%

102,700

0.008 %

TOTAL:

144,316

0.011%

114,377

0.009%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Purchase

1,100

72.24 USD

ADR - ISIN US0463531089

Purchase

442

72.25 USD

ADR - ISIN US0463531089

Purchase

1,600

72.26 USD

ADR - ISIN US0463531089

Purchase

200

72.27 USD

3342

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Sale

3,964

72.2 USD

3,964

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOABMMTMBTTBFI
Date   Source Headline
1st Sep 20203:00 pmRNSTotal Voting Rights
1st Sep 20207:00 amRNSImfinzi approved in EU for small cell lung cancer
1st Sep 20207:00 amRNSFarxiga reduces CKD progression and risk of death
25th Aug 20207:00 amRNSPh I trial begins for COVID-19 monoclonal antibody
21st Aug 20207:00 amRNSImfinzi approved in Japan for SCLC
18th Aug 20207:00 amRNSImfinzi US Priority Review; four-week, fixed dose
4th Aug 20207:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20203:00 pmRNSTotal Voting Rights
30th Jul 20207:25 amRNSTagrisso US BTD for EGFRm adjuvant lung cancer
30th Jul 20207:18 amRNSAZN: H1 2020 results
29th Jul 20207:00 amRNSBoard Committee Changes
28th Jul 20207:00 amRNSFarxiga DAPA-CKD trial met all endpoints
27th Jul 20207:10 amRNSCalquence receives positive CHMP opinion for CLL
27th Jul 20207:05 amRNSImfinzi recommended for EU approval in SCLC
27th Jul 20207:00 amRNSAstraZeneca enters collaboration in oncology
24th Jul 20207:00 amRNSBreztri Aerosphere approved in the US for COPD
22nd Jul 20203:00 pmRNSHolding(s) in Company
22nd Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
20th Jul 20202:41 pmRNSCOVID-19 vaccine Phase I/II showed immune response
16th Jul 20207:00 amRNSDirector Declaration
9th Jul 20207:00 amRNSBrilinta granted US FDA Priority Review for stroke
8th Jul 20207:00 amRNSLynparza approved in the EU for pancreatic cancer
1st Jul 20203:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSSelumetinib granted Japan orphan drug designation
17th Jun 20203:03 pmRNSHolding(s) in Company
17th Jun 20203:00 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSAgreement to Supply Europe with COVID-19 Vaccine
11th Jun 20207:00 amRNSEMTN Programme Routine Technical Update
1st Jun 20203:00 pmRNSBlock listing Interim Review
1st Jun 20203:00 pmRNSTotal Voting Rights
1st Jun 20207:00 amRNSLynparza EU CHMP opinion in pancreatic cancer
1st Jun 20207:00 amRNSBrilinta obtains additional US approval
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:35 pmRNSPrice Monitoring Extension
29th May 20201:00 pmRNSImfinzi sustained overall survival in CASPIAN
29th May 20201:00 pmRNSEnhertu DESTINY-Gastric01 results from ASCO 2020
29th May 20207:00 amRNSTagrisso unprecedented adjuvant lung cancer data
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.